SNT Stock Analysis: Synektik S.A. | WAR
Medical Devices | WAR, Poland | Market Cap: 2.850m PLN | 12M Return: 30% | PLSNKTK00019 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.50M
EPS Trend: 84.9%
Rev. Trend: 87.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Synektik S.A. is a Poland-based healthcare equipment and services company supplying medical systems for surgery, diagnostic imaging, and nuclear medicine. It also develops radiology IT solutions, produces radiopharmaceuticals used in oncology diagnostics, and provides equipment maintenance and testing services. Its business combines equipment sales with software, specialist services, and diagnostic products.
- Da Vinci system deliveries and recurring service revenue drive growth
- Polish hospital investment and EU funding support equipment demand
- Radiopharmaceutical expansion lifts oncology diagnostics growth potential
| Net Income: 417.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 18.89 > 1.0 |
| NWC/Revenue: 13.32% < 20% (prev 14.40%; Δ -1.08% < -1%) |
| CFO/TA 0.31 > 3% & CFO 176.0m > Net Income 417.3m |
| Net Debt (-10.5m) to EBITDA (247.0m): -0.04 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (8.53m) vs 12m ago 0.0% < -2% |
| Gross Margin: 35.02% > 18% (prev 34.48%; Δ 0.54% > 0.5%) |
| Asset Turnover: 193.3% > 50% (prev 156.2%; Δ 37.04% > 0%) |
| Interest Coverage Ratio: 73.14 > 6 (EBIT TTM 226.0m / Interest Expense TTM 3.09m) |
| A: 0.22 (Total Current Assets 392.3m - Total Current Liabilities 268.1m) / Total Assets 565.8m |
| B: 0.25 (Retained Earnings 141.1m / Total Assets 565.8m) |
| C: 0.47 (EBIT TTM 226.0m / Avg Total Assets 482.5m) |
| D: 0.61 (Book Value of Equity 214.2m / Total Liabilities 351.6m) |
| Altman-Z'' = 6.04 = AAA |
| DSRI: 1.28 (Receivables 248.5m/129.8m, Revenue 932.7m/623.9m) |
| GMI: 0.98 (GM 34.48% / 35.02%) |
| AQI: 0.90 (AQ_t 0.15 / AQ_t-1 0.16) |
| SGI: 1.49 (Revenue 932.7m / 623.9m) |
| TATA: 0.43 (NI 417.3m - CFO 176.0m) / TA 565.8m) |
| Beneish M = -2.47 (Cap -4..+1) = BBB |
As of October 29, 2026, the stock is trading at PLN 330.40 with a total of 17,084 shares traded. Over the past week, the price has changed by -5.22%, over one month by -5.06%, over three months by -8.88% and over the past year by +29.95%.
Current recommended Stop Loss: 318.60 (which is 3.6% or 1.2 ATR below the current price).
Synektik S.A. has no consensus analysts rating.
P/E Trailing = 16.0673
P/E Forward = 16.3666
P/S = 3.0552
P/B = 13.2918
Revenue TTM = 932.7m PLN
EBIT TTM = 226.0m PLN
EBITDA TTM = 247.0m PLN
Long Term Debt = 11.3m PLN (from longTermDebt, last quarter)
Short Term Debt = 10.4m PLN (from shortTermDebt, last quarter)
Debt = 68.3m PLN (from shortLongTermDebtTotal, last quarter) + Leases 26.7m
Net Debt = -10.5m PLN (calculated: Debt 68.3m - CCE 78.7m)
Enterprise Value = 2.84b PLN (2.85b + Debt 68.3m - CCE 78.7m)
Interest Coverage Ratio = 73.14 (Ebit TTM 226.0m / Interest Expense TTM 3.09m)
EV/FCF = 18.53x (Enterprise Value 2.84b / FCF TTM 153.3m)
FCF Yield = 5.40% (FCF TTM 153.3m / Enterprise Value 2.84b)
FCF Margin = 16.43% (FCF TTM 153.3m / Revenue TTM 932.7m)
Net Margin = 44.75% (Net Income TTM 417.3m / Revenue TTM 932.7m)
Gross Margin = 35.02% ((Revenue TTM 932.7m - Cost of Revenue TTM 606.0m) / Revenue TTM)
Gross Margin QoQ = 32.36% (prev 36.69%)
Tobins Q-Ratio = 5.02 (Enterprise Value 2.84b / Total Assets 565.8m)
Interest Expense / Debt = 4.53% (Interest Expense 3.09m / Debt 68.3m)
Taxrate = 19.21% (42.2m / 219.6m)
NOPAT = 182.6m (EBIT 226.0m * (1 - 19.21%))
Current Ratio = 1.46 (Total Current Assets 392.3m / Total Current Liabilities 268.1m)
Debt / Equity = 0.32 (Debt 68.3m / totalStockholderEquity, last quarter 214.2m)
Debt / EBITDA = -0.04 (Net Debt -10.5m / EBITDA 247.0m)
Debt / FCF = -0.07 (Net Debt -10.5m / FCF TTM 153.3m)
Total Stockholder Equity = 213.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 86.49% (Net Income 417.3m / Total Assets 565.8m)
RoE = 195.5% (Net Income TTM 417.3m / Total Stockholder Equity 213.5m)
RoCE = 100.6% (EBIT 226.0m / Capital Employed (Equity 213.5m + L.T.Debt 11.3m))
RoIC = 69.85% (NOPAT 182.6m / Invested Capital 261.4m)
WACC = 7.60% (E(2.85b)/V(2.92b) * Re(7.69%) + D(68.3m)/V(2.92b) * Rd(4.53%) * (1-Tc(0.19)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -17.41 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈105.1m ; Y1≈120.4m ; Y5≈177.2m
[DCF] Fair Price = 313.9 (EV 2.67b - Net Debt -10.5m = Equity 2.68b / Shares 8.53m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.86 | EPS CAGR: 81.30% | SUE: N/A | # QB: 0
Revenue Correlation: 86.99 | Revenue CAGR: 19.50% | SUE: 0.16 | # QB: 0
EPS current Year (2026-09-30): EPS=20.53 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+40.0% | GrowthRev=+40.0%
EPS next Year (2027-09-30): EPS=22.06 | Chg30d=+5.62% | Revisions=+25% | GrowthEPS=+7.4% | GrowthRev=-2.7%
[Analyst] Revisions Ratio: +40% (up=2, down=0)